3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Leukemia, Myeloid, Acute
32
Myelodysplastic Syndromes
28
Multiple Myeloma
27
Precursor Cell Lymphoblastic Leukemia-Lymphoma
26
Hodgkin Disease
12
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
11
Lymphoma, Non-Hodgkin
10
Lymphoma
10
Hematologic Neoplasms
10
Neuroblastoma
9
Myeloproliferative Disorders
9
Anemia, Refractory, with Excess of Blasts
8
Lymphoma, Mantle-Cell
7
Leukemia, Myelomonocytic, Chronic
7
Leukemia
7
Neoplasms, Plasma Cell
6
Lymphoma, T-Cell
6
Leukemia, Biphenotypic, Acute
6
Graft vs Host Disease
6
Leukemia, Lymphocytic, Chronic, B-Cell
5
Burkitt Lymphoma
5
Recurrence
4
Primary Myelofibrosis
4
Melanoma
4
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, Follicular
4
Leukemia, Myelomonocytic, Juvenile
4
Hematologic Diseases
4
Ganglioneuroblastoma
4
Anemia, Aplastic
4
Interventions
Gemcitabine
113
130-nm albumin-bound paclitaxel
64
Albumin-Bound Paclitaxel
43
Fluorouracil
37
Magnetic Resonance Spectroscopy
35
pembrolizumab
34
Irinotecan
34
Taxes
33
Specimen Handling
33
Leucovorin
33
Oxaliplatin
31
Biopsy
22
Cyclophosphamide
21
Nivolumab
18
fludarabine
16
Radiosurgery
16
Cisplatin
16
Drug Therapy
15
Capecitabine
12
folfirinox
11
durvalumab
11
Radiotherapy
11
irinotecan sucrosofate
10
Ipilimumab
10
Cetuximab
10
Carboplatin
10
Blood Specimen Collection
10
olaparib
9
Standard of Care
9
dehydroftorafur
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
Melphalan
×
1 year
×
Clear all
NCT04150042
2026-01-29
SHARON
General Oncology, Inc.
Phase 1
Recruiting
24 enrolled